AIMT

AIMT Articles

Are Aimmune Shareholders Getting Enough in the Buyout?
The prize for Nestle in its acquisition of Aimmune Therapeutics is Palforzia, the world’s first treatment for a food allergy.
Chris Lange
Published:

Nestle Adds Peanut Allergy Treatment to Its Portfolio
Consumer products giant Nestlé has agreed to acquire Aimmune Therapeutics, maker of a peanut-allergy treatment. The deal is valued at $2.6 billion, including Nestlé's existing stake Aimmune.
Paul Ausick
Published:

Top Analyst Upgrades and Downgrades: AbbVie, AES, AT&T, Boeing, Carnival, CME, Coca-Cola, Comcast, Honeywell, Lululemon, Netflix, Shopify, Starbucks, Twitter and More
Monday's top analyst calls included AbbVie, AES, AT&T, Boeing, Carnival, CME, Coca-Cola, Comcast, Honeywell, Lululemon Athletica, Netflix, Shopify, Starbucks and Twitter.
Jon C. Ogg
Published: